No business profile yet.
Size Taidoc Technology (4736.TW) is a Taiwan Health Care company (Medical Specialties) with a market value of $387M, the 518th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$124.00 on 18 Nov 2026.
Performance Over six months the shares gained 0.4%, against -22.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue fell 0.5% over the last twelve months (peer median +14.7%); the operating margin is 19.2% (peer median 4.2%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.1× (8th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$4.32B | NT$4.20B | NT$4.64B | NT$4.81B | NT$9.63B |
| Revenue growth | — | -9% | -3% | -50% | — |
| Gross profit | NT$1.86B | NT$1.90B | NT$2.01B | NT$2.02B | NT$5.59B |
| EBITDA | NT$965M | NT$1.10B | NT$979M | NT$1.20B | NT$4.37B |
| Net income | NT$2.26B | NT$1.44B | NT$1.16B | NT$1.02B | NT$3.38B |
| Free cash flow | NT$738M | NT$739M | NT$734M | NT$1.28B | NT$3.77B |
| Capital expenditure | NT$363M | NT$251M | NT$355M | NT$114M | NT$508M |
| Total debt | NT$894M | NT$1.16B | NT$1.05B | NT$1.09B | NT$636M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4736.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.1% | -12.6% | 5th highest of 21 |
| 6-month return | +0.4% | -22.4% | 5th highest of 20 |
| Distance from 52-week high | -15.1% | -45.3% | 2nd highest of 21 |
| Revenue growth (TTM) | -0.5% | +14.7% | 6th lowest of 21 |
| Operating margin | 19.2% | 4.2% | 6th highest of 21 |
| EV / Sales | 1.8× | 4.1× | 8th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -9.5% | 5.7% | 4th least demanding of 12 |
| Growth delivered (Del g) | -6.6% | +15.9% | lowest of 12 |
| Hurdle (Req g minus delivered) | -2.9 pp | +1.8 pp | 5th least demanding of 12 |
| ROIC minus cost of capital | +4.7 pp | -2.1 pp | 9th highest of 20 |
| EV / EBITDA | 8.1× | 11.6× | 4th cheapest of 9 |
| Net debt / EBITDA | -5.5× | -1.2× | 2nd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | 7.1× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 1.4× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 3.9× | 9.6% | +5.6% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | 17.8× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | 4.4× | n/a | n/a |